88 related articles for article (PubMed ID: 36748474)
1. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM;
Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810
[TBL] [Abstract][Full Text] [Related]
2. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxic effects of angiogenesis inhibitors.
Dobbin SJH; Petrie MC; Myles RC; Touyz RM; Lang NN
Clin Sci (Lond); 2021 Jan; 135(1):71-100. PubMed ID: 33404052
[TBL] [Abstract][Full Text] [Related]
4. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830
[TBL] [Abstract][Full Text] [Related]
5. Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies.
Hsu PY; Mammadova A; Benkirane-Jessel N; Désaubry L; Nebigil CG
Front Cardiovasc Med; 2021; 8():694711. PubMed ID: 34386529
[TBL] [Abstract][Full Text] [Related]
6. How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor.
Rashidi A; Wanchoo R; Izzedine H
Clin J Am Soc Nephrol; 2023 Jan; 18(1):121-123. PubMed ID: 35977777
[No Abstract] [Full Text] [Related]
7. Impact of Hypertension in Cancer Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
Minegishi S
Circ J; 2024 Jan; 88(2):226-227. PubMed ID: 36709968
[No Abstract] [Full Text] [Related]
8. Microvascular Dysfunction in Obesity-Hypertension.
Do T; Van A; Ataei A; Sharma S; Mohandas R
Curr Hypertens Rep; 2023 Dec; 25(12):447-453. PubMed ID: 37837517
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies.
Gomez JA
Am Heart J Plus; 2022 May; 17():100144. PubMed ID: 38559889
[TBL] [Abstract][Full Text] [Related]
10. Cullin 3 and Blood Pressure Regulation: Insights From Familial Hyperkalemic Hypertension.
Maeoka Y; Cornelius RJ; McCormick JA
Hypertension; 2023 May; 80(5):912-923. PubMed ID: 36861484
[TBL] [Abstract][Full Text] [Related]
11. Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage.
Wang W; Li G; Ma J; Fan X; Lu J; Sun Q; Yao J; He Q
Front Pharmacol; 2024; 15():1346905. PubMed ID: 38405666
[TBL] [Abstract][Full Text] [Related]
12. Progression of Carotid Intima-Media Thickness Partly Indicates the Prevention of Hypertension among Older Individuals in the General Population.
Shimizu Y
Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511963
[TBL] [Abstract][Full Text] [Related]
13. VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
le Noble FAC; Mourad JJ; Levy BI; Struijker-Boudier HAJ
Hypertension; 2023 May; 80(5):901-911. PubMed ID: 36748474
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
15. Vascular toxicity associated with anti-angiogenic drugs.
Neves KB; Montezano AC; Lang NN; Touyz RM
Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
17. Cardiac epigenetic changes in VEGF signaling genes associate with myocardial microvascular rarefaction in experimental chronic kidney disease.
Eirin A; Chade AR
Am J Physiol Heart Circ Physiol; 2023 Jan; 324(1):H14-H25. PubMed ID: 36367693
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
Thanigaimani S; Kichenadasse G; Mangoni AA
Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
